Brief: Partner Advances Gubra Originated Obesity Triple Agonist Peptide Into Phase 2
April 28 (Reuters) - Gubra A/S GUBRA.CO: BOEHRINGER INGELHEIM ADVANCES GUBRA ORIGINATED OBESITY TRIPLE AGONIST PEPTIDE INTO PHASE 2 DEVELOPMENT Source text: ID:nMFN7CfVNK Further company coverage: GUBRA.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Gubra A/S
See all newsBrief: Gubra Q1 EBIT Amounts To DKK -41.3 Million
Brief: Partner Advances Gubra Originated Obesity Triple Agonist Peptide Into Phase 2
Brief: Gubra's Partner Abbvie Reports Positive Phase 1 Results For ABBV-295
Brief: Gubra 2025 Group Operating Profit At DKK 2.2 Billion
Brief: Gubra Submits Clinical Trial Application For GUB-UCN2 In Germany